H ypertension contributes importantly to heightened cardiovascular risk in blacks, in whom it is more common and more severe than in whites. Despite more intensive therapy, only 48% of treated blacks meet blood pressure (BP) goals.
OSA (REI ≥30 events/h) was independently associated with 3.58 times higher odds of resistant hypertension relative to non-OSA (REI <5 events/h). A graded relationship was evident between severity of OSA and resistance to treatment.
Several clinically relevant observations emerge from this work. First, most of those with REI ≥15 (94%) were undiagnosed, which reaffirms the alarmingly widespread lack of recognition of OSA in blacks, even in those with high-risk conditions like hypertension. The second notable finding relates to hypoxemia, a key mechanism mediating OSA-induced pathology. 7 Intermittent hypoxemia stimulates chemoreflex-mediated central sympathetic outflow, renin-angiotensin-aldosterone system activation, angiogenesis, generation of reactive oxygen species and oxidative stress, and cytokine release, promoting inflammation and endothelial dysfunction. Hypoxemia is hence a strong predictor of unfavorable outcomes, often outperforming respiratory indexes such as the apnea-hypopnea index that are traditionally used to diagnose and rate OSA severity. From a pathophysiological perspective, the body senses and responds to hypoxemia and not to a respiratory index, which is a convenient but artificial metric of sleep apnea severity. Indeed, Johnson and colleagues 4 show that nocturnal hypoxemia was significantly related to risk of resistant hypertension, and they should be particularly commended for exploring the predictive value of different degrees of oxygen desaturation associated with abnormal breathing.
This leads to the third observation of compelling clinical relevance. Although differences between operational definitions of hypopnea requiring ≥3% or ≥4% desaturation would seem negligible, there is considerable impact on OSA prevalence and prognostic significance. Only OSA defined by the ≥4% desaturation (and not the 3%) threshold was significantly associated with resistant hypertension, echoing findings from the Sleep Heart Health Study, in which only hypopneas that induced at least 4% oxygen desaturation portended increased risk of cardiovascular disease. 8 Also, recent results from the MESA study (Multi-Ethnic Study of Atherosclerosis) indicate that this 4% threshold is more strongly associated with BP. 9 Importantly, use of the more inclusive 3% cutoff would preclude detection of such an association, hindering recognition of the significance of OSA in resistant hypertension, and plausibly in other outcomes. The actionable relation between this degree of hypoxemia and outcomes challenges the current sleep scoring rules, 6 which recommend concomitant ≥3% desaturation or arousal to score hypopneas, leading to marked increases in OSA diagnoses. Although it is understandable that we should not miss OSA, lowering diagnostic thresholds increases prevalence, obscures relevance to meaningful outcomes, and can understandably generate caregiver complacency regarding need for therapeutic intervention. If everything is OSA, then nothing is OSA.
Finally, we need to consider why OSA and resistant hypertension interact so strongly. Although sympathetic overdrive, volume overload, and excess aldosterone are thought to be primary culprits, the nexus between OSA and resistant hypertension is likely not restricted to direct biological mechanisms that raise BP and reduce responsiveness to therapy, but also via other pathways, which are conceivably potentiated in blacks. Adherence to antihypertensive drugs is low among blacks, and hypertensive patients at high risk of OSA exhibit reduced compliance with medications. 10 Moreover, daytime sleepiness, a sentinel symptom of OSA, is more frequent in blacks and accounts for a large proportion of nonadherence to antihypertensive regimens. 11 Recognizing these behavioral and other factors will more quickly lead to developing remediation strategies.
A potential weakness of the study, noted by the authors, is the lack of ambulatory BP monitoring. Out-ofoffice BP, preferably ambulatory BP, is recommended to rule out white-coat resistant hypertension.
3 Ambulatory BP, particularly related to nighttime measures, outperforms conventional office BP, and its superior prognostic value is especially evident among blacks. Moreover, there is an urgent need for comprehensive and longitudinal BP phenotyping in blacks with resistant hypertension and concurrent OSA, to better discern temporal patterns and track progression.
Their data nevertheless make a compelling argument for improved detection and management of OSA in blacks. Barriers to OSA screening and treatment acceptance, such as access to health care and awareness of health implications of OSA, can be overcome by implementation of culturally tailored education programs for both providers and communities, interactions with racially concordant healthcare staff, and increased accessibility of sleep testing. Preliminary data from similar initiatives to enhance OSA screening are encouraging. 12 Recent findings from the Jackson Heart Study, showing that heart failure is more common in blacks and that overall adiposity, as measured by body mass index, is independently associated with an increased risk of incident heart failure, 13 speak directly to these objectives. Given the high prevalence of undiagnosed OSA in blacks and the direct relationship between body mass index and OSA, it is likely that occult OSA may have contributed to incident heart failure, in part by increasing BP. A pivotal question, however, is whether treating OSA will lower BP or risk of outcomes such as heart failure.
Although current guidelines 3 recommend identification and correction of comorbid OSA in resistant hypertension, whether treating OSA lowers BP significantly remains unclear. Antihypertensive effects of continuous positive airway pressure (CPAP), the therapy of choice for OSA, are generally modest, but patients with drugresistant hypertension can experience greater changes, with pooled reductions of about −6 mm Hg estimated from randomized controlled trials, 14 along with improved nocturnal BP. Nevertheless, achievement of target BP with CPAP is unproven, and because of the short follow-up of most of these studies, evaluation of longterm benefits is elusive. Furthermore, there is substantial variability in responsiveness, because the magnitude of BP decline is largely a function of adherence to CPAP. This is especially problematic because CPAP compliance is notoriously suboptimal, and tolerance is further diminished in blacks. Moreover, in spite of improvements in sleep, daytime symptoms, and intermediate outcomes, recent large-scale randomized controlled trials such as the SAVE trial (Sleep Apnea Cardiovascular Endpoints) 15 failed to demonstrate survival advantages of CPAP. Notably, because underrepresentation of blacks in clinical trials persists (<1% of participants in SAVE were black), it is unclear to what extent such findings can be extrapolated to this population. Similar considerations on generalizability can be made regarding the preferred antihypertensive drug class in OSA, or combination therapy of CPAP and antihypertensive agents, which also lack robust efficacy data. Rigorous randomized controlled trials to inform on optimal pharmacological management of high BP in OSA, with emphasis on targeted BP control strategies in high-risk groups, are urgently warranted.
Given the devastating, disproportionate toll of high BP in blacks, identifying and eradicating sources of inequality in hypertension risk and consequences are a national priority. As also advocated by the American Heart Association, 1 it is time to bring to center stage the role of sleep in these disparities. Johnson and colleagues 4 take an important step toward answering this call to action. Understanding the contribution of sleep disorders and sleep habits in the excessive cardiovascular risk experienced by blacks, as well as the potential benefits of normalizing sleep, could go a long way toward mitigating such disparities. 
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